HIV protease: Enzyme function and drug resistance

Vitamins and Hormones

Volumn 58, Issue , 2000, Pages 213-256

  Gulnik, Sergei ^a   Erickson, John W ^a   Xie, Dong ^a  

^a SAIC FREDERICK INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEINASE; PROTEINASE INHIBITOR;

AMINO ACID SEQUENCE; ANTIBIOTIC RESISTANCE; BINDING SITE; CHEMISTRY; DIMERIZATION; DRUG EFFECT; ENZYME SPECIFICITY; ENZYMOLOGY; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS; METABOLISM; MUTATION; REVIEW; THERMODYNAMICS;

AMINO ACID SEQUENCE; BINDING SITES; DIMERIZATION; DRUG RESISTANCE, MICROBIAL; HIV; HIV PROTEASE; HIV PROTEASE INHIBITORS; MUTATION; SUBSTRATE SPECIFICITY; THERMODYNAMICS;

EID: 0033628818     PISSN: 00836729     EISSN: None     Source Type: Book Series    
DOI: 10.1016/s0083-6729(00)58026-1     Document Type: Review

References (168)

1. P.J. Ala E.E. Huston R.M. Klabe D.D. McCabe J.L. Duke C.J. Rizzo B.D. Korant R.J. DeLoskey P.Y. Lam C.N. Hodge C.H. Chang Molecular basis of HIV-1 protease drug resistance: Structural analysis of mutant proteases complexed with cyclic urea inhibitors Biochemistry 36 1997 1573 1580
2. R. Ala R. DeLoskey E. Huston P. Jadhav P. Lam C. Eyermann C. Hodge M. Schadt F. Lewandowski P. Weber D. McCabe J. Duke C. Chang Molecular recognition of cyclic urea HIV-1 protease inhibitors J. Biol. Chem. 273 1998 12325 12331
3. E.T. Baldwin T.N. Bhat S. Gulnik B. Liu I.A. Topol Y. Kiso T. Mimoto H. Mitsuya J.W. Erickson Structure of HIV-1 protease with KNI-272, a tight-binding transition-state analog containing allophenylnorstatine Structure 3 1995 581 590
4. E.T. Baldwin T.N. Bhat B. Liu N. Pattabiraman J.W. Erickson Structural basis of drug resistance for the V82A mutant of HIV-1 proteinase Nat. Struct. Biol. 2 1995 244 249
5. K.A. Barrie E.E. Perez S.L. Lamers W.G. Farmerie B.M. Dunn J.W. Sleasman M.M. Goodenow Natural variation in HIV-1 protease, Gag p7 and p6, and protease cleavage sites within gag/polpolyproteins: Amino acid substitutions in the absence of protease inhibitors in mothers and children infected by human immunodeficiency virus type 1 Virology 219 1996 407 416
6. M. Barry S. Gibvons D. Back F. Mulcahy Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations Clin. Pharmacokinet. 32 1997 194 209
7. A. Billich F. Hammerschmid G. Winkler Purification, assay and kinetic features of HIV-1 proteinase Biol. Chem. Hoppe-Seyler 371 1990 265 272
8. D. Boden M. Markowitz Resistance to human immunodeficiency virus type 1 protease inhibitors Antimicrob. Agents Chemother. 42 1998 2775 2783
9. A. Carrillo K.D. Stewart H.L. Sham D.W. Norbeck W.E. Kohlbrenner J.M. Leonard D.J. Kempf A. Molla In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378, a novel protease inhibitor J. Virol. 72 1998 7532 7541
10. Z. Chen Y. Li H.B. Schock D. Hall E. Chen L.C. Kuo Three-dimensional structure of a mutant HIV-1 protease displaying cross-resistance to all protease inhibitors in clinical trials J. Biol. Chem. 270 1995 21433 21436
11. Y.-S.E. Cheng F.H. Yin S. Foundling D. Blomstrom C.A. Kettner Stability and activity of human immunodeficiency virus protease: Comparison of the natural dimer with a homologous, single-chain tethered dimer Proc. Natl. Acad. Sci. U.S.A. 87 1990 9660 9664
12. J.M. Coffin HIV population dynamics in vivo : Implications for genetic variation, pathogenesis and therapy Science 267 1995 483 489
13. J.M. Coffin S.H. Hughes H.E. Varmus Retroviruses 1997 Cold Spring Harbor Lab. Press Cold Spring Harbor, NY
14. J.R. Collins S.K. Burt J.W. Erickson Flap opening in HIV-1 protease simulated by ‘activated’ molecular dynamics Nat. Struct. Biol. 2 1995 334 338
15. J.H. Condra W.A. Schleif O.M. Blahy L.J. Gabryelski D.J. Graham J.C. Quintero A. Rhodes H.L. Robbins E. Roth M. Shivaprakash D. Titus T. Yang H. Teppler K.E. Squires P.J. Deutsch E.A. Emini In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors Nature (London) 374 1995 569 571
16. J.H. Condra D.J. Holder W.A. Schleif O.M. Blahy R.M. Danovich L.J. Gabryelski D.J. Graham D. Laird J.C. Quintero A. Rhodes H.L. Robbins E. Roth M. Shivaprakash T. Yang J.A. Chodakewitz P.J. Deutsch R.Y. Leavitt F.E. Massari J.W. Mellors K.E. Squires R.T. Steigbigel H. Teppler E.A. Emini Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor J. Virol. 70 1996 8270 8276
17. M. Cornelissen R. van den Burg F. Zorgdrager V. Lukashov J. Goudsmit pol gene diversity of five human immunodeficiency virus type 1 subtypes: Evidence for naturally occurring mutations that contribute to drug resistance, limited recombination patterns, and common ancestry for subtypes B and D J. Virol. 71 1997 6348 6358
18. G. Croteau L. Doyon D. Thibeault G. McKercher L. Pilote D. Lamarre Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors J. Virol. 71 1997 1089 1096
19. P.L. Darke Stability of dimeric retroviral proteases L.C. Kuo J.A. Shafer Methods in Enzymology Vol. 241 1994 Academic Press San Diego, CA 104 127
20. P.L. Darke S.P. Jordan D.L. Hall J.A. Zugay J.A. Shafer L.C. Kuo Dissociation and association of the HIV-1 protease dimer subunits: Equilibria and rates Biochemistry 33 1994 98 105
21. D.R. Davies The structure and function of the aspartic proteinases Annu. Rev. Biophys. Biomol. Struct. 19 1990 189 215
22. C. Debouck The HIV-1 protease as a therapeutic target for AIDS AIDS Res. Hum. Retroviruses 8 1992 153 164
23. C. Debouck J.G. Gorniak J.E. Strickler T.D. Meek B.W. Metcalf M. Rosenberg Human immunodeficiency virus protease expressed in Escherichia coli exhibits autoprocessing and specific maturation of the gag precursor Proc. Natl. Acad. Sci. U.S.A. 84 1987 8903 8906
24. S.G. Deeks M. Smith M. Holodniy J.O. Kahn HIV-1 protease inhibitors. A review for clinicians JAMA, J. Am. Med. Assoc. 277 1997 145 153
25. B.D. Dorsey R.B. Levin S.L. McDaniel J.P. Vacca J.P. Guare P.L. Darke J.A. Zugay E. Emini W.A. Schleif J.C. Quintero J.H. Lin I.-W. Chen M.K. Holloway P.M.D. Fitzgerald M.G. Axel D. Ostovic P.S. Anderson J.R. Huff L-735,524: The design of a potent and orally bioavailable HIV protease inhibitor J. Med. Chem. 37 1994 3443 3451
26. L. Doyon G. Croteau D. Thibeault F. Poulin L. Pilote D. Lamarre Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors J. Virol. 70 1996 3763 3769
27. B.M. Dunn A. Gustchina A. Wlodawer J. Kay Subsite preferences of retroviral proteinases L.C. Kuo J.A. Shafer Methods of Enzymology Vol. 241 1994 Academic Press San Diego, CA 254 278
28. P. Eastman J. Mittler R. Kelso C. Gee E. Boyer J. Kolberg M. Urdea J. Leonard D. Norbeck H. Mo M. Markowitz Genotypic changes in human immunodeficiency virus type 1 associated with loss of suppression of plasma viral RNA levels in subjects treated with ritonavir (norvir) monotherapy J. Virol. 72 1998 5154 5164
29. 2 symmetric inhibitor complexed to HIV-1 protease Science 249 1990 527 533
30. J.W. Erickson The not-so-great escape Nat. Struct. Biol. 2 1995 523 529
31. J.W. Erickson S.K. Burt Structural mechanisms of HIV drug resistance Annu. Rev. Pharmacol. Toxicol. 36 1996 545 571
32. J.W. Erickson M.E. Eissenstat HIV protease as a target for the design of antiviral agents for AIDS B. Dunn Proteases of Infectious Agents 1999 Academic Press San Diego, CA 1 60
33. J.W. Erickson S.V. Gulnik M. Markowitz Protease inhibitors: Resistance, cross-resistance, fitness and the choice of initial and salvage therapies AIDS 13 Suppl A 1999 S189 S204
34. J. Ermolieff X. Lin J. Tang Kinetic properties of saquinavir-resistant mutants of human immunodeficiency virus type 1 protease and their implications in drug resistance in vivo Biochemistry 36 1997 12364 12370
35. D.M. Ferguson R.J. Radmer P.A. Kollman Determination of the relative binding free energies of peptide inhibitors to the HIV-1 protease J. Med. Chem. 34 1991 2654 2659
36. C. Flexner HIV-protease inhibitors N. Engl. J. Med. 338 1998 1281 1292
37. E. Freire O.L. Mayorga M. Straume Isothermal titration calorimetry. Direct thermodynamic characterization of biological molecular interactions Anal. Chem. 62 1990 950A 959A
38. E.S. Furfine E. D'Souza K.J. Ingold J.J. Levan T. Spector D.J. Porter Two-step binding mechanism for HIV protease inhibitors Biochemistry 31 1992 7886 7891
39. S. Grant I. Deckman J. Culp M. Minnich I. Brooks P. Hensley C. Debouck T. Meek Use of protein unfolding studies to determine the conformational and dimeric stabilities of HIV-1 and SIV protease Biochemistry 31 1992 9491 9501
40. ∗pro- cleavage sites Biochemistry 31 1992 5193 5200
41. S.V. Gulnik L.I. Suvorov B. Liu B. Yu B. Anderson H. Mitsuya J.W. Erickson Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure Biochemistry 34 1995 9282 9287
42. J. Hammond B.A. Larder R.F. Schinazi J.W. Mellors Mutation in retroviral genes associated with drug resistance B. Korber B. Foley T. Leither F. McCutchan B. Hahn J.W. Mellors G. Myers C. Kuiken Human Retroviruses and AIDS 1997 III 207-III-249 Los Alamos, NM
43. W.E. Harte Jr. D.L. Beveridge Prediction of the protonation state of the active site aspartyl residues in HIV-1 protease-inhibitor complexes via molecular dynamics simulation J. Am. Chem. Soc. 115 1993 3883 3886
44. C.U.T. Hellen Assay methods for retroviral proteases L.C. Kuo J.A. Shafer Methods of Enzymology Vol. 241 1994 Academic Press San Diego, CA 46 58
45. Mne) J. Virol. 62 1988 2587 2595
46. K. Hertogs S. Kemp S. Bloor V. Miller S. Staszewski J. Mellors C. van den Eynde F. Peeters B. Larder R. Pauwels Patterns of cross-resistance among protease inhibitors in over 1500 clinical HIV-1 isolates. Comparison of genotypic and phenotypic resistance profiles Int. Workshop HIV Drug Resist. Treat. Strategies, 2nd 24–27 June, 1998, Lake Maggiore, Italy 1998 49 Abstract 70
47. 2-symmetric protease inhibitor J. Virol. 68 1994 2016 2020
48. C.N. Hodge P.E. Aldrich L.T. Bacheler C.H. Chang C.J. Eyermann S. Garber M. Grubb D.A. Jackson P.K. Jadhav B. Korant P.Y. Lam M.B. Maurin J.L. Meek M.J. Otto M.M. Rayner C. Reid T.R. Sharpe L. Shum D.L. Winslow S. Erickson-Viitanen Improved cyclic urea inhibitors of the HIV-1 protease: Synthesis, potency, resistance profile, human pharmacokinetics and X-ray crystal structure of DMP 450 Chem. Biol. 3 1996 301 314
49. S.S. Hoog E.M. Towler B. Zhao M.L. Doyle C. Debouck S.S. Abdel-Meguid Human immunodeficiency virus protease ligand specificity conferred by residues outside of the active site cavity Biochemistry 35 1996 10279 10286
50. J.O. Hui A.G. Tomasselli I.M. Reardon J.M. Lull D.P. Brunner C.S. Tomich R.L. Heinrikson Large scale purification and refolding of HIV-1 protease from Escherichia coli inclusion bodies J. Protein Chem. 12 1993 323 327
51. L.J. Hyland T.A. Tomaszek Jr. T.D. Meek Human immunodeficiency virus-1 protease. 2. Use of pH rate studies and solvent kinetic isotope effects to elucidate details of chemical mechanism Biochemistry 30 1991 8454 8463
52. E. Ido H.P. Han F.J. Kezdy J. Tang Kinetic studies of human immunodeficiency virus type 1 protease and its active-site hydrogen vond mutant A28S J. Biol. Chem. 266 1991 24359 24366
53. H. Jacobsen M. Hanggi M. Ott I.B. Duncan S. Owen M. Andreoni S. Vella J. Mous In vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: Mutations, kinetics, and frequencies J. Infect. Dis. 173 1996 1379 1387
54. P.K. Jadhav P. Ala F.J. Woerner C.H. Chang S.S. Garber E.D. Anton L.T. Bacheler Cyclic urea amides: HIV-1 protease inhibitors with low nanomolar potency against both wild type and protease inhibitor resistant mutants of HIV J. Med. Chem. 40 1997 181 191
55. S. Jordan J. Zugay P. Darke L. Kuo Activity and dimerization of human immunodeficiency virus protease as a function of solvent composition and enzyme concentration J. Biol. Chem. 267 1992 20028 20032
56. S.W. Kaldor V.J. Kalish J.F. Davies 2nd B.V. Shetty J.E. Fritz K. Appelt J.A. Burgess K.M. Campanale N.Y. Chirgadze D.K. Clawson B.A. Dressman S.D. Hatch D.A. Khalil M.B. Kosa P.P. Lubbehusen M.A. Muesing A.K. Patick S.H. Reich K.S. Su J.H. Tatlock Viracept (nelfinavir mesylate, AG1343): A potent, orally bioavailable inhibitor of HIV-1 protease J. Med. Chem. 40 1997 3979 3985
57. A.H. Kaplan R. Swanstrom Human immunodeficiency virus type 1 Gag proteins are processed in two cellular compartments Proc. Natl. Acad. Sci. U.S.A. 88 1991 4528 4532
58. A.H. Kaplan J.A. Zack M. Knigge D.A. Paul D.J. Kempf D.W. Norbeck R. Swanstrom Partial inhibition of the human immunodeficiency virus type 1 protease results in aberrant virus assembly and the formation of noninfectious particles J. Virol. 67 1993 4050
59. A.H. Kaplan M. Manchester R. Swanstrom The activity of the protease of human immunodeficiency virus type 1 is initiated at the membrane of infected cells before the release of viral proteins and is required for release to occur with maximum efficiency J. Virol. 68 1994 6782 6786
60. A.H. Kaplan S.F. Michael R.S. Wehbie M.F. Knigge D.A. Paul L. Everitt D.J. Kempf D.W. Norbeck J.W. Erickson R. Swanstrom Selection of multiple human immunodeficiency virus type 1 variants that encode viral proteases with decreased sensitivity to an inhibitor of the viral protease Proc. Natl. Acad. Sci. U.S.A. 91 1994 5597 5601
61. I. Katoh T. Yasunaga Y. Ikawa Y. Yoshinaka Inhibition of retroviral protease activity by an aspartyl proteinase inhibitor Nature (London) 329 1987 654 656
62. D.J. Kempf K.C. Marsh J.F. Denissen E. McDonald S. Vasavanonda C.A. Flentge B.E. Green L. Fino C.H. Park X.P. Kong ABT-538 is a potent inhibitor of human immunodeficiency virus protease and as high oral bioavailability in humans Proc. Natl. Acad. Sci. U.S.A. 92 1995 2484 2488
63. D.J. Kempf R.A. Rode Y. Xu E. Sun M.E. Heath-Chiozzi J. Valdes A.J. Japour S. Danner C. Boucher A. Molla J.M. Leonard The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir AIDS 12 1998 F9 F14
64. C.U. Kim L.R. McGee S.H. Krawczyk E. Harwood Y. Harada S. Swaminathan N. Bischofberger M.S. Chen J.M. Cherrington S.F. Xiong L. Griffin K.C. Cundy A. Lee B. Yu S. Gulnik J.W. Erickson New series of potent, orally bioavailable, non-peptidic cyclic sulfones as HIV-1 protease inhibitors J. Med. Chem. 39 1996 3431 3434
65. A.F. Kisselev R. Mentele K. von der Helm Cleavage of the complement system C3 component by HIV-1 proteinase Biol. Chem. Hoppe-Seyler 378 1997 439 442
66. R.M. Klabe L.T. Bacheler P.J. Ala S. Erickson-Viitanen J.L. Meek Resistance to HIV protease inhibitors: A comparison of enzyme inhibition and antiviral potency Biochemistry 37 1998 8735 8742
67. N.E. Kohl E.A. Emini W.A. Schleif L.J. Davis J.C. Heimbach R.A.F. Dixon E.M. Scolnick I.S. Sigal Active human immunodeficiency virus protease is required for viral infectivity Proc. Natl. Acad. Sci. U.S.A. 85 1988 4686 4690
68. J. Konvalinnka P. Strop J. Velek V. Cerna V. Kostka L.H. Phylip A.D. Richards B.M. Dunn J. Kay Sub-site preferences of the aspartic proteinase from the human immunodeficiency virus, HIV-1 FEBS Lett. 268 1990 35 38
69. J. Konvalinka M. Horejsi M. Andreansky P. Novek I. Pichova I. Blaha M. Fabry J. Sedlacek S. Foundling P. Strop An engineered retroviral proteinase from myeloblastosis associated virus acquires pH dependence and substrate specificity of the HIV-1 proteinase EMBO J. 11 1992 1141 1144
70. B.D. Korant C.J. Rizzo The HIV protease and therapies for AIDS Adv. Exp. Med. Biol. 421 1997 279 284
71. B.D. Korant P. Strack M.W. Frey C.J. Rizzo A cellular anti-apoptosis protein is cleaved by the HIV-1 protease Adv. Exp. Med. Biol. 436 1998 27 29
72. M. Kotler G. Arad S. Hughes Human immunodeficiency virus type 1 Gag-protease fusion proteins are enzymatically active J. Virol. 66 1992 6781 6783
73. M. Kotler M. Simm Y.S. Zhao P. Sova W. Chao S.F. Ohnona R. Roller C. Krachmarov M.J. Potash D.J. Volsky Human immunodeficiency virus type 1 (HIV-1) protein Vif inhibits the activity of HIV-1 protease in bacteria and in vitro J. Virol. 71 1997 5774 5781
74. M.J. Kozal N. Shah N. Shen R. Yang R. Fucini T.C. Merigan D.D. Richman D. Morris E. Hubbell M. Chee T.R. Gingeras Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays Nat. Med. 2 1996 753 759
75. G.A. Krafft G.T. Wang Synthetic approaches to continuous assays of retro-viral proteases L.C. Kuo J.A. Shafer Methods in Enzymology Vol. 241 1994 Academic Press San Diego, CA 70 86
76. R.A. Kramer M.D. Schaber A.M. Skalka K. Ganguly S.F. Wong E.P. Reddy HTLV-III gag protein is processed in yeast cells by the virus pol-protease Science 231 1986 1580 1584
77. H.-G. Kräusslich M. Fäcke A.-M. Heuser J. Konvalinka H. Sentgraf The spacer peptide between human immonodeficiency virus capsid and nucleocapsid proteins is essential for ordered assembly and viral infectivity J. Virol. 69 1995 3407 3419
78. P. Kuzmic C. Garcia-Echeverria D.H. Rich Stabilization of HIV proteinase dimer by bound substrate Biochem. Biophys. Res. Commun. 194 1993 301 305
79. J. Ladbury B. Chowdhry Sensing the heat: The application of isothermal titration calorimetry to the thermodynamic studies of biomolecular interactions Chem. Biol. 3 1996 791 801
80. P.Y.S. Lam P.K. Jadhav C.J. Eyermann C.N. Hodge Y. Ru L.T. Bacheler J.L. Meek M.J. Otto M.M. Rayner Y.N. Wong C.-H. Chang P.C. Weber D.A. Jackson T.R. Sharpe S. Erickson-Viitanen Rational design of potent, bioavailable, nonpeptide cyclic ureas as HIV protease inhibitors Science 263 1994 380 384
81. R. Lapatto T. Blundell A. Hemmings J. Overington A. Wilderspin S. Wood J.R. Merson P.J. Whittle D.E. Danley K.F. Geoghegan S.J. Hawrylik S.E. Lee K. Scheld P.M. Hobart X-ray analysis of HIV-1 proteinase at 2.7Å resolution confirms structural homology among retroviral enzymes Nature (London) 342 1989 299 302
82. W.J. Lech G. Wang Y.L. Yang Y. Chee K. Dorman D. McCrae L.C. Lazzeroni J.W. Erickson J.S. Sinsheimer A.H. Kaplan In vivo sequence diversity of the protease of human immunodeficiency virus type 1: Presence of protease inhibitor-resistant variants in untreated subjects J. Virol. 70 1996 2038 2043
83. C.S. Lee N. Choy C. Park H. Choi Y.C. Son S. Kim J.H. Ok H. Yoon S.C. Kim Design, synthesis, and characterization of dipeptide isostere containing cis-epoxide for the irreversible inactivation of HIV protease Bioorg. Med. Chem. Lett. 6 1996 589 594
84. I. Luque M. Todd J. Gomez N. Semo E. Freire Molecular basis of resistance to HIV-1 protease inhibition: A plausible hypothesis Biochemistry 37 1998 5791 5797
85. F. Mammano C. Petit F. Clavel Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: Phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients J. Virol. 72 1998 7632 7637
86. M. Markowitz H. Mo D.J. Kempf D.W. Norbeck T.N. Bhat J.W. Erickson D.D. Ho Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor J. Virol. 69 1995 701 706
87. J. Martinez-Picado A. Savara L. Sutton R. D'Aquila Replicative fitness of protease inhibitor resistant mutants of human immunodeficiency virus type 1 J. Virol. 73 1999 3744 3752
88. B. Maschera G. Darby G. Palu L.L. Wright M. Tisdale R. Myers E.D. Blair E.S. Furfine Human immunodeficiency virus. Mutations in the viral protease that confer resistance to saquinavir increase the dissociation rate constant of the protease-saquinavir complex J. Biol. Chem. 271 1996 33231 33235
89. T.J. McQuade A.G. Tomasselli L. Liu V. Karacostas B. Moss T.K. Sawyer R.L. Heinrikson W.G. Tarpley A synthetic HIV-1 protease inhibitor with antiviral activity arrests HIV-like particle maturation Science 247 1990 454 456
90. T.D. Meek B.D. Dayton B.W. Metcalf G.B. Dreyer J.E. Strickler J.G. Gorniak M. Rosenberg M.L. Moore V.W. Magaard C. Debouck Human immunodeficiency virus 1 protease expressed in Escherichia coli behaves as a dimeric aspartic protease Proc. Natl. Acad. Sci. U.S.A. 86 1989 1841 1845
91. T.D. Meek E.J. Rodriguez T.S. Angeles Use of steady state kinetic methods to elucidate the kinetic and chemical mechanisms of retroviral proteases L.C. Kuo J.A. Shafer Methods in Enzymology Vol. 241 1994 Academic Press San Diego, CA 127 156
92. A.M. Mildner D.J. Rothrock J.W. Leone C.A. vannow J.M. Lull I.M. Reardon J.L. Sarcich W.J. Howe C.-S.C. Tomich C.W. Smith R.L. Heinrikson A.G. Tomasselli The HIV-1 protease as enzyme and substrate: Mutagenesis of autolysis sites and generation of a stable mutant with retained kinetic properties Biochemistry 33 1994 9405 9413
93. A. Molla M. Korneyeva Q. Gao S. Vasavanonda P.J. Schipper H.M. Mo M. Markowitz T. Chernyavskiy P. Niu N. Lyons A. Hsu G.R. Granneman D.D. Ho C.A. Boucher J.M. Leonard D.W. Norbeck D.J. Kempf Ordered accumulation of mutations in HIV protease confers resistance to ritonavir Nat Med. 2 1996 760 766
94. A. Molla G.R. Granneman E. Sun D.J. Kempf Recent developments in HIV protease inhibitor therapy Antiviral Res. 39 1998 1 23
95. G. Moyle B. Gazzard Current knowledge and future prospects for the use of HIV protease inhibitors Drugs 51 1996 701 712
96. K.P. Murphy E. Freire Thermodynamics of structural stability and cooperative folding behavior in proteins Adv. Protein Chem. 43 1992 313 361
97. M.A. Navia P.M.D. Fitzgerald B.M. McKeever C.-T. Leu J.C. Heimbach W.K. Herber I.S. Sigal P.L. Darke J.P. Springer Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1 Nature (London) 337 1989 615 620
98. M. Nijhuis R. Schuurman D. Jong J. Erickson E. Gustchina J. Albert P. Schipper S. Gulnik C.A.B. Boucher Increased fitness of drug resistant HIV-1 variants as a result of continued replication during suboptimal therapy 1999 Submitted for publication
99. U. Nillroth L. Vrang P. Markgren J. Hulten A. Hallberg H. Danielson Human immunodeficiency virus type 1 proteinase resistance of symmetric cyclic urea inhibitor analogs Antimicrob. Agents Chemother. 41 1997 2383 2388
100. S. Noble D. Faulds Saquinavir. A review of its pharmacology and clinical potential in the management of HIV infection Drugs 52 1996 93 112
101. C.A. Pargellis M.M. Morelock E.T. Graham P. Kinkade S. Pav K. Lubbe D. Lamarre P.C. Anderson Determination of kinetic rate constants for the binding of inhibitors to HIV-1 protease and for the association and dissociation of active homodimer Biochemistry 33 1994 12527 12534
102. 2-symmetric HIV-1 protease inhibitors Bioorg. Med. Chem. Lett. 5 1995 1843 1848
103. J.A. Partaledis K. Yamaguchi M. Tisdale E.E. Blair C. Falcione B. Maschera R.E. Myers S. Pazhanisamy O. Futer A.B. Cullinan C.M. Stuver R.A. Byrn D.J. Livingston In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease J. Virol. 69 1995 5228 5235
104. A.K. Patick R. Rose J. Greytok C.M. Bechtold M.A. Hermsmeier P.T. Chen J.C. Barrish R. Zahler R.J. Colonno P.-E. Lin Characterization of a human immunodeficiency virus type 1 variant with reduced sensitivity to an aminodiol protease inhibitor J. Virol. 69 1995 2148 2152
105. A.K. Patick H. Mo M. Markowitz K. Appelt B. Wu L. Musick V. Kalish S. Kaldor S. Reich D. Ho S. Webber Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease Antimicrob. Agents Chemother. 40 1996 292 297
106. S. Pazhanisamy C.M. Stuver A.B. Cullinan N. Margolin B.G. Rao D.J. Livingston Kinetic characterization of human immunodeficiency virus type-1 protease-resistant variants J. Biol. Chem. 271 1996 17979 17985
107. L.H. Pearl W.R. Taylor A structural model for the retroviral proteases Nature (London) 329 1987 351 354
108. S. Pettit M. Moody R. Wehbie A. Kaplan P. Nantermet C. Klein R. Swantstrom The p2 domain of human immunodeficiency virus type 1 Gag regulates sequential proteolytic processing and is required to produce fully infectio virions J. Virol. 68 1994 8017 8027
109. L.H. Phylip A.D. Richards J. Kay J. Konvalinka P. Strop I. Bláha J. Velek V. Kostka A.J. Ritchie A.V. Broadhurst W.G. Farmerie P.E. Scarborough B.M. Dunn Hydrolysis of synthetic chromogenic substrates by HIV-1 and HIV-2 proteinases Biochem. Biophys. Res. Commun. 171 1990 439 444
110. L. Polgár Z. Szeltner I. Boros Substrate-dependent mechanisms in the catalysis of human immunodeficiency virus protease Biochemistry 33 1994 9351 9357
111. R.A. Poorman A.G. Tomasselli R.L. Heinrikson F.J. Kézdy A cumulative specificity model for proteases from human immunodeficiency virus types 1 and 2, inferred from statistical analysis of an extended substrate data base J. Biol. Chem. 266 1991 14554 14561
112. J.V. Prasad E.A. Lunney D. Ferguson P.J. Tummino R.J. Rubin E.L. Reyner B.H. Stewart R.J. Guttendorf J.M. Domagala L.I. Suvorov S.V. Gulnik I.A. Topol T.N. Bhat J.W. Erickson HIV protease inhibitors possessing a novel, high affinity and achiral P1/P2 ligand with unique pattern of in vitro resistance. Importance of conformationally-restricted template in the design of enzyme inhibitors J. Am. Chem. Soc. 117 1995 11070 11074
113. J.V. Prasad E.A. Lunney K.S. Para P.J. Tummino D. Ferguson D. Hupe J.M. Domagala J.W. Erickson Nonpeptidic potent HIV-1 protease inhibitors Drug Des. Discovery 13 1996 15 28
114. L. Quere T. Wenger H.J. Schramm Triterpenes as potential dimerization inhibitors of HIV-1 protease Biochem. Biophys. Res. Commun. 227 1996 484 488
115. A.D. Richards L.H. Phylip W.G. Farmerie P.E. Scarborough A. Alverez B.M. Dunn P.-H. Hirel J. Konvalinka L. Pavlickova V. Kostka J. Kay Sensitive, soluble chromogenic substrates for HIV-1 proteinase J. Biol. Chem. 265 1990 7733 7736
116. T. Ridky J. Leis Development of drug resistance to HIV-1 protease inhibitors J. Biol. Chem. 270 1995 29621 29623
117. T.W. Ridky A. Kikonyogo J. Leis S. Gulnik T. Copeland J. Erickson A. Wlodawer I. Kurinov R.W. Harrison I.T. Weber Drug-resistant HIV-1 proteases identify enzyme residues important for substrate selection and catalytic rate Biochemistry 37 1998 13835 13845
118. Y. Riviere V. Blank P. Kourilsky A. Israel Processing of the precursor of NF-kappa B by the HIV-1 protease during acute infection Nature (London) 350 1991 625 626
119. N.A. Roberts J.C. Craig J. Sheldon Resistance and cross-resistance with saquinavir and other HIV protease inhibitors: Theory and practice AIDS 12 1998 453 460
120. N.A. Roberts J.A. Martin D. Kinchington A.V. Broadhurst J.C. Craig I.B. Duncan S.A. Galpin B.K. Handa J. Kay A. Kröhn R.W. Lambert J.H. Merrett J.S. Mills K.E.B. Parkes S. Redshaw A.J. Ritchie D.L. Taylor G.J. Thomas P.J. Machin Rational design of peptide-based HIV proteinase inhibitors Science 248 1990 358 361
121. J.R. Rose R. Salto C.S. Craik Regulation of autoproteolysis of the HIV-1 and HIV-2 proteases with engineered amino acid substitutions J. Biol. Chem. 268 1993 11939 11945
122. J.R. Rose L.M. Babe C.S. Craik Defining the level of human immunodeficiency virus type 1 (HIV-1) protease activity required for HIV-1 particle maturation and infectivity J. Virol. 69 1994 2751 2758
123. R. Rose C. Craik R. Stroud Domain flexibility in retroviral proteases: Structural implications for drug resistant mutations Biochemistry 37 1998 2606 2621
124. R.E. Rose Y.F. Gong J.A. Greytok C.M. Bechtold B.J. Terry B.S. Robinson M. Alam R.J. Colonno P.F. Lin Human immunodeficiency virus type 1 viral background plays a major role in development of resistance to protease inhibitors Proc. Natl. Acad. Sci. U.S.A. 93 1996 1648 1653
125. I. Schechter A. Berger On the size of the active site in proteases. I. Papain Biochem. Biophys. Res. Commun. 27 1967 157 162
126. H.B. Schock V.M. Garsky L.C. Kuo Mutational anatomy of an HIV-1 protease variant conferring cross-resistance to protease inhibitors in clinical trials. Compensatory modulations of binding and activity J. Biol. Chem. 271 1996 31957 31963
127. H.J. Schramm J. Boetzel J. Buttner E. Fritsche W. Gohring E. Jaeger S. Konig O. Thumfart T. Wenger N.E. Nagel W. Schramm The inhibition of human immunodeficiency virus proteases by ‘interface peptides’ Antiviral Res. 30 1996 155 170
128. S. Seelmeier H. Schmidt V. Turk K. von der Helm Human immunodeficiency virus has an aspartic-type protease that can be inhibited by pepstatin A Proc. Natl. Acad. Sci. U.S.A. 85 1988 6612 6616
129. R.W. Shafer M.A. Winters S. Palmer T.C. Merigan Multiple concurrent reverse transcriptase and protease mutations and multidrug resistance of HIV-1 isolates from heavily treated patients Ann. Intern. Med. 128 1998 906 911
130. R.L. Shoeman B. Sachse E. Honer E. Mothes M. Kaufmann P. Traub Cleavage of human and mouse cytoskeletal and sarcomeric proteins by human immunodeficiency virus type 1 protease: Actin, desmin, myosin, and tropomyosin Am. J. Pathol. 142 1993 221 230
131. A.M. Silva R.E. Cachau H.L. Sham J.W. Erickson Inhibition and catalytic mechanism of HIV-1 aspartic protease J. Mol. Biol. 255 1996 321 346
132. M.L. Smidt K.E. Potts S.P. Tucker L. Blystone T.R. Stiebel Jr. W.C. Stallings J.J. McDonald D. Pillay D.D. Richamn M.L. Bryant A mutation in human immunodeficiency virus type 1 protease at position 88, located outside the active site, confers resistance to the hydroxyethylurea inhibitor SC-55389A Antimicrob. Agents Chemother. 31 1997 515 522
133. R. Smith I.M. Brereton R.Y. Chai S.B. Kent Ionization states of the catalytic residues in HIV-1 protease Nat. Struct. Biol. 3 1996 946 950
134. J. Snasel I. Pichova The cleavage of host cell proteins by HIV-1 protease Folia Biol. 42 1996 227 230
135. J. Stebbins C. Debouck Expression systems for retroviral proteases L.C. Kuo J.A. Shafer Methods in Enzymology Vol. 241 1994 Academic Press San Diego, CA 3 16
136. J.E. Strickler J. Gorniak B. Dayton T. Meek M. Moore V. Magaard J. Malinowski C. Debouck Characterization and autoprocessing of precursor and mature forms of human immunodefiency virus type 1 (HIV 1) protease purified from Escherichia coli Proteins 6 1989 139 154
137. Z. Szeltner L. Polgár Rate-determining steps in HIV-1 protease catalysis. The hydrolysis of the most specific substrate J. Biol. Chem. 271 1996 32180 32184
138. J. Tang J.A. Hartsuck A kinetic model for comparing proteolytic processing activity and inhibitor resistance potential of mutant HIV-1 proteases FEBS Lett. 367 1995 112 116
139. J. Tang M.N.G. James I.N. Hsu J.A. Jenkins T.L. Blundell Structural evidence for gene duplication in the evolution of the acid proteases Nature (London) 271 1978 618 621
140. G.J. Tawa I. Topol S. Burt J.W. Erickson Calculation of relative binding free energies of peptidic inhibitors to HIV-1 protease and its I84V mutant J. Am. Chem. Soc. 120 1998 8856 8863
141. S. Thaisrivongs H.I. Skulnick S.R. Turner J.W. Strohbach R.A. Tommasi P.D. Johnson P.A. Aristoff T.M. Judge R.B. Gammill J.K. Morris K.R. Romines R.A. Chrusciel R.R. Hinshaw K.T. Chong W.G. Tarpley S.M. Poppe D.E. Slade J.C. Lynn M.M. Horng P.K. Tomich E.P. Seest L.A. Dolak W.J. Howe G.M. Howard Structure-based design of HIV protease inhibitors: Sulfonamide-containing 5,6-dihydro-4-hydroxy-2-pyrones as non-peptidic inhibitors J. Med. Chem. 39 1996 4349 4353
142. M.J. Todd N. Semo E. Freire The structural stability of the HIV-1 protease J. Mol. Biol. 283 1998 475 488
143. H. Toh M. Ono K. Saigo T. Miyata Retroviral protease-like sequence in the yeast transposon Ty1 Nature (London) 315 1985 691 692
144. A.G. Tomasselli R.L. Heinrikson Specificity of retroviral proteases: An analysis of viral and nonviral protein substrates L.C. Kuo J.A. Shafer Methods in Enzymology Vol. 241 1994 Academic Press San Diego, CA 279 301
145. A.G. Tomasselli W.J. Howe J.O. Hui T.K. Sawyer I.M. Reardon D.L. DeCamp C.S. Craik R.L. Heinrikson Calcium-free calmodulin is a substrate of proteases from human immunodeficiency viruses 1 and 2 Proteins 10 1991 1 9
146. A.G. Tomasselli J.O. Hui L. Adams J. Chosay D. Lowery B. Greenberg A. Yem M.R. Deibel H. Zürcher-Neely R.L. Heinrikson Actin, troponin C, Alzheimer amyloid precursor protein and pro-interleukin 1β as substrates of the protease from human immunodeficiency virus J. Biol. Chem. 266 1991 14548 14553
147. J. Tozser I.T. Weber A. Gustchina I. Blaha T.D. Copeland J.M. Louis S. Oroszlan Kinetic and modeling studies of S3-S3′ subsites of HIV proteinases Biochemistry 31 1992 4793 4800
148. J.P. Vacca Design of tight-binding human immunodeficiency virus type 1 protease inhibitors L.C. Kuo J.A. Shafer Methods in Enzymology Vol. 241 1994 Academic Press San Diego, CA 311 334
149. J.P. Vacca J.H. Condra Clinically effective HIV-1 protease inhibitors Drug Des. Discovery 2 1997 261 272
150. J.P. Vacca B.D. Dorsey W.A. Schleif R.B. Levin S.L. McDaniel P.L. Darke J. Zugai J.C. Quintero O.M. Blahy E. Roth V.V. Sardana A.J. Schlabach P.I. Graham J.H. Condra L. Gotlib M.K. Holloway J. Lin I.-W. Chen K. Vastag D. Ostovic P.S. Anderson E.A. Emini J.R. Huff L-735, 524: An orally bioavailable human immunodeficiency virus type 1 protease inhibitor Proc. Natl. Acad. Sci. U.S.A. 91 1994 4096 4100
151. V.M. Vogt Proteolytic processing and particle maturation Curr. Top. Microbiol. Immunol. 214 1996 95 131
152. Y.X. Wang D.I. Freedberg T. Yamazaki P.T. Wingfield S.J. Stahl J.D. Kaufman Y. Kiso D.A. Torchia Solution NMR evidence that the HIV-1 protease catalytic aspartyl groups have different ionization states in the complex formed with the asymmetric drug KNI-272 Biochemistry 35 1996 9945 9950
153. M.L. West D.P. Fairlie Targeting HIV-1 protease: A test of drug-design methodologies Trends Pharmacol. Sci. 16 1995 67 75
154. S.I. Wilson L.H. Phylip J.S. Mills S.V. Gulnik J.W. Erickson B.M. Dunn J. Kay Escape mutants of HIV-1 proteinase: Enzymic efficiency and susceptibility to inhibition Biochim. Biophys. Acta 1339 1997 113 125
155. D.L. Winslow M.J. Otto HIV protease inhibitors AIDS 9 Suppl. A 1995 S183 S192
156. M.A. Winters J.M. Schapiro J. Lawrence T.C. Merigan Human immunodeficiency virus type 1 protease genotypes and in vitro protease inhibitor susceptibilities of isolates from individuals who were switched to other protease inhibitors after long-term saquinavir treatment J. Virol. 72 1998 5303 5306
157. A. Wlodawer J.W. Erickson Structure-based inhibitors of HIV-1 protease Annu. Rev. Biochem. 62 1993 543 585
158. A. Wlodawer J. vondrasek Inhibitors of HIV-1 protease: A major success of structure-assisted drug design Annu. Rev. Biophys. Biomol. Struct. 27 1998 249 284
159. A. Wlodawer M. Miller M. Jaskólski B.K. Sathyanarayana E. Baldwin I.T. Weber L.M. Selk L. Clawson J. Schneider S.B.H. Kent Conserved folding in retroviral proteases: Crystal structure of a synthetic HIV-1 protease Science 245 1989 616 621
160. D. Xie S. Gulnik L. Collins E. Gustchina T.N. Bhat J.W. Erickson Thermodynamics and proton uptake for pepstatin binding to retroviral and eukaryotic aspartic proteases Adv. Exp. Med. Biol. 436 1998 381 386
161. D. Xie S. Gulnik E. Gustchina B. Yu W. Shao W. Qoronfleh A. Nathan J.W. Erickson Drug resistant mutations can affect dimer stability of HIV-1 protease at neutral pH Protein Sci. 8 1999 1702 1707
162. D. Xie L. Suvorov E. Gustchina J. Erickson S. Gulnik Real-time measurements of dark substrate catalysis Protein Sci. 1999 (in press)
163. T. Yamazaki L. Nicholson D. Torchia P. Wingfield S. Stahl J. Kaufman C. Eyermann N. Hodge P. Lam Y. Ru P. Jadhav C.-H. Chang P. Weber NMR and X-ray evidence that the HIV protease catalytic aspartyl groups are protonated in the complex formed by the protease and a non-peptide cyclic urea-based inhibitor J. Am. Chem. Soc. 116 1994 10791 10792
164. Z. Yu P. Caldera F. McPhee J.J. De Voss P.R. Jones A.L. Burlingame I.D. Kuntz C.S. Craik P.R. Ortiz de Montellano Irreversiible inhibition of the HIV-1 protease: Targeting alkylating agents to the catalytic aspartate groups J. Am. Chem. Soc. 118 1996 5846 5856
165. V. Zennou F. Mammano S. Paulous D. Mathez F. Clavel Loss of viral fitness associated with multiple Gag and Gag-Pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo J. Virol. 72 1998 3300 3306
166. Y.M. Zhang H. Imamichi T. Imamichi H.C. Lane J. Falloon M.B. Vasudevachari N.P. Salzman Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites J. Virol. 71 1997 6662 6670
167. Z.-Y. Zhang R.A. Poorman L.L. Maggiora R.L. Heinrikson F.J. Kézdy Dissociative inhibition of dimeric enzymes J. Biol. Chem. 266 1991 15591 15594
168. R. Zutshi J. Franciskovich M. Shultz B. Schweitzer P. Bishop M. Wilson J. Chmielewski Targeting the dimerization interface of HIV-1 protease-inhibition with cross-linked interfacial peptides J. Am. Chem. Soc. 119 1997 4841 4845